Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

The Lymphoma Channel is supported with funding from AstraZeneca (Diamond), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze).

VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.

Share this video  

EHA 2022 | Mechanisms of resistance to immunotherapy in NHL

Nilanjan Ghosh • 10 Jun 2022
EHA 2022
Lymphoma Non-Hodgkin Lymphoma

Nilanjan Ghosh, MD, PhD, Atrium Health Levine Cancer Institute, Charlotte, NC, briefly discusses mechanisms of resistance to immunotherapy in non-Hodgkin lymphoma (NHL), drawing focus on T-cell exhaustion, myeloid-derived suppressor cells, and antigen escape. This interview took place at the European Hematology Association (EHA) Congress 2022 held in Vienna, Austria.

Disclosures

Research funding, honoraria, consulting: BMS
Consulting: Lilly, Genentech/Roche

More from Nilanjan Ghosh

Long-term follow-up results of Mosun-Pola versus R-Pola in patients with R/R LBCL
6:42
Long-term follow-up results of Mosun-Pola versus R-Pola in patients with R/R LBCL
Nilanjan Ghosh • 10 Dec 2025
Evaluation of real-world venetoclax initiation prophylaxis & monitoring outcomes in CLL
2:31
Evaluation of real-world venetoclax initiation prophylaxis & monitoring outcomes in CLL
Nilanjan Ghosh • 10 Dec 2025
Key takeaways & trials from ICML in DLBCL, MCL, and FL: POLARGO, STARGLO, MorningSun & more
15:00
Key takeaways & trials from ICML in DLBCL, MCL, and FL: POLARGO, STARGLO, MorningSun & more
Nilanjan Ghosh • 27 Jun 2025
An overview of CAR T-cell therapies in the treatment of patients with MCL
6:46
An overview of CAR T-cell therapies in the treatment of patients with MCL
Nilanjan Ghosh • 26 Jun 2024

Related Videos

Genomic and immune signatures of ibrutinib response & resistance in Waldenström's macroglobulinemia
2:39
Genomic and immune signatures of ibrutinib response & resistance in Waldenström's macroglobulinemia
Tina Bagratuni • 23 Sep 2026
Unresolved questions in T-cell lymphoma: individualized therapy and access to new technologies
2:13
Unresolved questions in T-cell lymphoma: individualized therapy and access to new technologies
Mary Jo Lechowicz • 11 Sep 2026
Key advances in FL management expected to change practice over the next five years
1:26
Key advances in FL management expected to change practice over the next five years
Kim Linton • 11 Sep 2026
Community lymphoma management: which patients should be prioritized for specialist referral?
1:16
Community lymphoma management: which patients should be prioritized for specialist referral?
Nirav Niranjan Shah • 10 Sep 2026

Choose your cookie settings

VJHemOnc uses necessary cookies to make the site work. With your permission we'd also like to use analytics, preference and marketing cookies to understand how the site is used and improve it.

Choose an option to continue. You can change it at any time on our Cookie Policy page, linked at the bottom of every page.

Cookie Policy (opens in a new tab)
The content of VJHemOnc is intended for healthcare professionals